1. How many patients are currently (in the past 3 months) undergoing treatment for melanoma, and how many of these are BRAF+?
2. In the past 3 months, how many melanoma patients (any stage) were treated with the following?
a. Cobimetinib
b. Dabrafenib
c. Dabrafenib AND Trametinib
d. Encorafenib AND Binimetinib
e. Ipilimumab
f. Ipilimumab AND Nivolumab
g. Nivolumab
h. Pembrolizumab
i. Trametinib
j. Vemurafenib
k. Vemurafenib AND Cobimetinib
l. Other active systemic anti-cancer therapy
m. Palliative care only
3. If possible, could you please provide the patients treated in the past 3 months with the following therapies for metastatic melanoma ONLY?
a. Ipilimumab
b. Ipilimumab AND Nivolumab
c. Nivolumab
d. Pembrolizumab
e. Any other therapies
4. In the past 3 months how many patients were treated with the following for breast cancer?
a. Abemaciclib + Anastrozole/Exemestane/Letrozole
b. Abemaciclib + Fulvestrant
c. Alpelisib + Fulvestrant
d. Atezolizumab
e. Bevacizumab
f. Eribulin
g. Everolimus + Exemestane
h. Fulvestrant as a single agent
i. Gemcitabine + Paclitaxel
j. Lapatinib
k. Neratinib
l. Olaparib
m. Palbociclib + Anastrozole/Exemestane/Letrozole
n. Palbociclib + Fulvestrant
o. Pertuzumab + Trastuzumab + Docetaxel
p. Ribociclib + Anastrozole/Exemestane/Letrozole
q. Ribociclib + Fulvestrant
r. Talazoparib
s. Transtuzumab + Paclitaxel
t. Transtuzumab as a single agent
u. Trastuzumab emtansine
v. Any other active systemic anti-cancer therapy

Download response Melanoma and breast cancer. 120221